Composition, form of production and packaging
Tablets are almost white, round, flat, with bevelled edge, with a risk on one side and a stamp of "VASOBRAL" on the other.
1 tab.
alpha-dihydroergocryptin mesylate 4 mg
caffeine 40 mg
Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate, silicon dioxide colloidal anhydrous.
10 pieces. - blisters (1) - packs of cardboard.
10 pieces. - blisters (3) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2013.
PHARMACHOLOGIC EFFECT
Combined drug. ? -dihydroergocriptine - the dihydrated ergot derivative, blocks? 1 and? 2 adrenergic receptors. It has a dopaminergic, serotonergic effect, reduces platelet and erythrocyte aggregation, reduces the permeability of the vascular wall, increases the number of functioning capillaries, improves blood circulation and metabolic processes in the brain, increases the resistance of brain tissue to hypoxia.
Caffeine has a psychostimulating and analeptic effect, enhances the processes of excitation in the cerebral cortex - increases mental and physical performance, reduces fatigue and drowsiness, increases the reflex excitability of the spinal cord, excites the respiratory and vasomotor centers, and has a diuretic effect.
PHARMACOKINETICS
When taken orally, the absorption of dihydroergocryptin is accelerated in the presence of caffeine (T max - 0.5 hours).
Maximum concentration after oral administration of 8 mg? - dihydroergocryptin is 227 pg / ml, and the half-life is less than 2 hours.
INDICATIONS
- reduction of mental activity, violation of attention and memory,
disturbance of orientation in space, caused by age
changes;
cerebrovascular insufficiency (including
cerebral atherosclerosis);
- consequences of cerebrovascular accident;
- prevention of migraine;
- vestibular and labyrinthine disturbances (dizziness, noise
in the ears, hypoacusis) ischemic genesis;
- MГ©niГЁre's disease;
- retinopathy (diabetic and hypertensive);
- violations of peripheral arterial blood circulation
(syndrome and Raynaud's disease);
- Venous insufficiency.
DOSING MODE
Inside (during a meal, with a small amount of liquid) to 1 / 2-1 tablet 2 times a day. The duration of the course of treatment is 2-3 months, if necessary, treatment courses can be repeated.
SIDE EFFECT
From the gastrointestinal tract: nausea, gastralgia, dyspepsia, with these manifestations, the drug is not required to be withdrawn.
Rarely (no more than 1% of cases) - dizziness, agitation, headache.
Very rarely (not more than 0.1% of cases) are possible allergic reactions, tachycardia, hypotension.
CONTRAINDICATIONS
- increased individual sensitivity to the components of the drug.
PREGNANCY AND LACTATION
There are no clinical data on the use of Vazobrala during pregnancy and lactation.
The use of the drug in the period of breastfeeding can lead to a decrease in lactation.
SPECIAL INSTRUCTIONS
Vasobrail has a vasodilating effect, without affecting the systemic blood pressure. The appointment of Vasobrail to patients with hypertension does not exclude the need for the use of antihypertensive agents.
The caffeine contained in the preparation can cause sleep disturbances, tachycardia.
OVERDOSE
Symptoms - increased severity of side effects. Treatment is symptomatic.
DRUG INTERACTION
With the simultaneous appointment of Vasobrail and hypotensive drugs, it is possible to develop arterial hypotension.
Caffeine weakens the effect of hypnotics.
TERMS OF RELEASE FROM PHARMACY
On prescription.
TERMS AND CONDITIONS OF STORAGE
List B. At a temperature of 15-25 В° C, out of reach of children. Shelf life - 4 years.
